Navigation Links
Mayo Clinic researchers identify new enzyme to fight Alzheimer's disease
Date:9/17/2012

JACKSONVILLE, Fla. An enzyme that could represent a powerful new tool for combating Alzheimer's disease has been discovered by researchers at Mayo Clinic in Florida. The enzyme known as BACE2 destroys beta-amyloid, a toxic protein fragment that litters the brains of patients who have the disease. The findings were published online Sept. 17 in the science journal Molecular Neurodegeneration.

Alzheimer's disease is the most common memory disorder. It affects more that 5.5 million people in the United States. Despite the disorder's enormous financial and personal toll, effective treatments have not yet been found.

The Mayo research team, led by Malcolm A. Leissring, Ph.D., a neuroscientist at Mayo Clinic in Florida, made the discovery by testing hundreds of enzymes for the ability to lower beta-amyloid levels. BACE2 was found to lower beta-amyloid more effectively than all other enzymes tested. The discovery is interesting because BACE2 is closely related to another enzyme, known as BACE1, involved in producing beta-amyloid.

"Despite their close similarity, the two enzymes have completely opposite effects on beta-amyloid BACE1 giveth, while BACE2 taketh away," Dr. Leissring says.

Beta-amyloid is a fragment of a larger protein, known as APP, and is produced by enzymes that cut APP at two places. BACE1 is the enzyme responsible for making the first cut that generates beta-amyloid. The research showed that BACE2 cuts beta-amyloid into smaller pieces, thereby destroying it, instead. Although other enzymes are known to break down beta-amyloid, BACE2 is particularly efficient at this function, the study found.

Previous work had shown that BACE2 can also lower beta-amyloid levels by a second mechanism: by cutting APP at a different spot from BACE1. BACE2 cuts in the middle of the beta-amyloid portion, which prevents beta-amyloid production.

"The fact that BACE2 can lower beta-amyloid by two distinct mechanisms makes this enzyme an especially attractive candidate for gene therapy to treat Alzheimer's disease," says first author Samer Abdul-Hay, Ph.D., a neuroscientist at Mayo Clinic in Florida.

The discovery suggests that impairments in BACE2 might increase the risk of Alzheimer's disease. This is important because certain drugs in clinical use for example, antiviral drugs used to treat human immunodeficiency virus (HIV) work by inhibiting enzymes similar to BACE2.

Although BACE2 can lower beta-amyloid by two distinct mechanisms, only the newly discovered mechanism beta-amyloid destruction is likely relevant to the disease, the researchers note. This is because the second mechanism, which involves BACE2 cutting APP, does not occur in the brain. The researchers have obtained a grant from the National Institutes of Health to study whether blocking beta-amyloid destruction by BACE2 can increase the risk for Alzheimer's disease in a mouse model of the disease.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinic-based community program helps with childhood obesity
2. PARP inhibitors may have clinical utility in HER2-positive breast cancers
3. Maturitas publishes clinical guide on low-dose vaginal estrogens for vaginal atrophy
4. New national clinical trials network for neurological disorders to foster cutting-edge treatments
5. New clinical guidelines for managing hypothyroid disease presented in Thyroid Journal
6. Epigenetics emerges powerfully as a clinical tool
7. Mayo Clinic suicide prevention expert outlines new steps to tackle military suicide
8. Physicians empathy directly associated with positive clinical outcomes, confirms large study
9. When clinicians and researchers look outside the box
10. Suicide prevention, telemedicine among topics at Mayo Clinic Transform 2012
11. Joint EACPR and AHA statement empowers health care professional to use Clinical Cardiopulmonary Exercise Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... 22, 2017 , ... Zifam Pinnacle, an Australian company dedicated to providing a ... retail buyers at the January ECRM Trade Show in Hilton Head, SC. , Zifam ... standards in all of its creations to help create a more traditional and natural ...
(Date:1/21/2017)... ... 2017 , ... "ProDOF is the perfect set of tools for video editors that want to ... said Christina Austin - CEO of Pixel Film Studios. , Video editors using ProDOF ... of a DSLR racking focus from one area into the next. ProDOF comes with ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... new medical office in Petaluma, located at 167 Lynch Creek Way. The Petaluma ... SRO sports medicine and rehabilitation services and on-site x-ray services. Two ...
(Date:1/20/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a ... Yisrayl says this generation is a time like no other and society needs to understand ... Yisrayl says he does not want to sound like an old bible beater because religion ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based ... recently attended the January ECRM Trade Show in Hilton Head, SC, benefiting from ... large range of supplements that keep the body functioning at its peak performance ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Research and Markets has announced the ... and Future" report to their offering. ... This research service on the global ... and provides a snapshot of the key participants in the market. ... provided from 2016 to 2020. The market is expected to grow ...
(Date:1/19/2017)... Germany Cataract Surgery Devices Market Outlook ... Cataract Surgery Devices Market Outlook to 2022", provides key ... The report provides value, in millions of US dollars, ... segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices (OVD). ... shares data for each of these market segements, and ...
(Date:1/19/2017)... WASHINGTON , Jan. 19, 2017 Conference Call and ... VNDA ) today announced it will release results for the ... market closes. ... Vanda will host a conference call at 4:30 PM ET on ... quarter and full year 2016 financial results and other corporate activities. ...
Breaking Medicine Technology: